Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00542880 |
This study is to assess the effects with two different inhaled respiratory medications with regards to improvement of lung function, symptoms and morning activities.
Condition | Intervention | Phase |
---|---|---|
Chronic Obstructive Pulmonary Disease (COPD) |
Drug: Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg Drug: Seretide Diskus (salmeterol/fluticasone) 50/500 μg Drug: Bricanyl Turbuhaler (terbutaline sulphate) 0.5 mg as relieve Other: Placebo Turbuhaler, one inhalation twice daily Other: Placebo Diskus, one inhalation twice daily |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Active Control, Crossover Assignment, Efficacy Study |
Official Title: | A Double-Blind, Randomised, Cross-Over, Multi-Centre Study, to Evaluate Onset of Effect in the Morning in Patients With Severe COPD Treated With Symbicort®Turbuhaler®) 320/9 μg, Compared With Seretide® Diskus®) 50/500 μg, Both Given as One Inhalation Twice Daily for One Week Each. |
Estimated Enrollment: | 450 |
Study Start Date: | September 2007 |
Ages Eligible for Study: | 40 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Tomas Andersson, MD | AstraZeneca |
Principal Investigator: | Martyn R Partridge, MD FRCP | Faculty of Medicine, Imperial College, NHLI at Charing Cross Hospital, LONDON, UK |
Study ID Numbers: | D5892C00016 |
Study First Received: | October 10, 2007 |
Last Updated: | August 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00542880 |
Health Authority: | Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica; Australia: Department of Health and Ageing Therapeutic Goods Administration; Belgium: Ministerie Van Sociale Zaken; Brazil: National Health Surveillance Agency; Denmark: Danish Medicines Agency; Germany: Bundesinstitut für Arzneimittel und Medizin; India: Drug Controller General; Philippines: Bureau of Food and Drugs; United Kingdom: Information Processing Unit - Area 6 |
COPD Symbicort Seretide |
Lung Diseases, Obstructive Salmeterol Symbicort Respiratory Tract Diseases Lung Diseases Respiration Disorders |
Budesonide Formoterol Fluticasone Terbutaline Pulmonary Disease, Chronic Obstructive |
Anti-Inflammatory Agents Respiratory System Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Adrenergic Agents Adrenergic beta-Agonists Sympathomimetics Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Anti-Asthmatic Agents |
Reproductive Control Agents Hormones Glucocorticoids Pharmacologic Actions Adrenergic Agonists Tocolytic Agents Autonomic Agents Therapeutic Uses Peripheral Nervous System Agents Bronchodilator Agents |